ISSN |
2218-4333 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Review |
Article Title |
Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review
|
Manuscript Source |
Invited Manuscript |
All Author List |
Mariana Miranda Sampaio, Maria Luísa Cordeiro Santos, Hanna Santos Marques, Vinícius Lima de Souza Gonçalves, Glauber Rocha Lima Araújo, Luana Weber Lopes, Jonathan Santos Apolonio, Camilo Santana Silva, Luana Kauany de Sá Santos, Beatriz Rocha Cuzzuol, Quézia Estéfani Silva Guimarães, Mariana Novaes Santos, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Márcio Vasconcelos Oliveira, Cláudio Lima Souza and Fabrício Freire de Melo |
Funding Agency and Grant Number |
|
Corresponding Author |
Fabrício Freire de Melo, MSc, PhD, Postdoc, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Rua Hormindo Barros, 58, Quadra 17, Lote 58, Vitória da Conquista 45029-094, Bahia, Brazil. freiremelo@yahoo.com.br |
Key Words |
Chronic myeloid leukemia; Breakpoint cluster region-Abelson murine leukemia; Immunotherapy; Tyrosine kinase inhibitors; Philadelphia chromosome; Diagnosis |
Core Tip |
The Chronic myeloid leukemia is a clonal hematopoietic stem cell disorder with a well understood pathogenesis. In this sense, the research is directed towards new therapeutic alternatives and understanding of immunobiology considering the growing resistance to standard therapy with tyrosine kinase inhibitors. This article aims to summarize the clinical approach and emerging therapeutic alternatives considering the adverse effects of new drugs, transplants and immunotherapy. |
Publish Date |
2021-02-22 12:47 |
Citation |
Sampaio MM, Santos MLC, Marques HS, Gonçalves VLS, Araújo GRL, Lopes LW, Apolonio JS, Silva CS, Santos LKS, Cuzzuol BR, Guimarães QES, Santos MN, de Brito BB, da Silva FAF, Oliveira MV, Souza CL, de Melo FF. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World J Clin Oncol 2021; 12(2): 69-94 |
URL |
https://www.wjgnet.com/2218-4333/full/v12/i2/69.htm |
DOI |
https://dx.doi.org/10.5306/wjco.v12.i2.69 |